Menopause Research

Introduction Menopause marks the end of reproductive life, but it is also the start of significant physiological shifts

Introduction A July 2026 clinical review, authored by a team of psychiatrists from institutions across Europe and the US, positions the antidepressant d…

Introduction For many women, the transition through perimenopause and menopause brings the frustrating experience of “brain fog”—difficulties with memor…

Desvenlafaxine: A Targeted Treatment for Menopause-Linked Cognitive Fog A serotonin-noradrenaline reuptake inhibitor (SNRI) called desvenlafaxine is eme…

Desvenlafaxine Identified as a First-Line Option for Depression, Including in Menopause A new clinical review led by psychiatrists from the University o…

Desvenlafaxine’s Dual-Action Offers New Path for Menopause-Related Brain Fog and Cognitive Dysfunction A comprehensive review published in Clinical Drug…

Desvenlafaxine Shows Promise for Perimenopausal Cognitive Dysfunction and Depression A new international consensus review positions the antidepressant d…

Introduction A 2026 consensus review led by researchers from the University of Pisa, Charité Berlin, and the Sant Pau Research Institute offers clinical…

Desvenlafaxine: A Proposed First-Line Antidepressant for Menopausal Cognitive Dysfunction A 2026 international review proposes that the antidepressant d…

Understanding the Brain Fog and Depression Connection in Menopause An international research team has identified the antidepressant desvenlafaxine as a …